ideology-health
  • Our Solutions
  • About Us
  • Dr. Tara Graff discusses the dosing and administration of mosunetuzumab in relapsed/refractory follicular lymphoma along with recent data on the subcutaneous formulation. (Video 2/3)
    Sign up to watch this video

    Free access to all Sound Bites content

    Dr. Tara Graff discusses the dosing and administration of mosunetuzumab in relapsed/refractory follicular lymphoma along with recent data on the subcutaneous formulation. (Video 2/3)

    Published on: March 26, 2025


    T

    Tara Graff, MD

    Medical Professional


    Mosun-SQ data

    Related Videos
    Dr. Tara Graff discusses the 5-year efficacy of Pola-R-CHP in LBCL (Video 1/3)

    Dr. Tara Graff discusses the 5-year efficacy of Pola-R-CHP in LBCL (Video 1/3)

    Tara Graff, MD
    Dr. Eric Singhi describes differentiating safety aspects of cemiplimab in patients with aNSCLC (Video 3/3)

    Dr. Eric Singhi describes differentiating safety aspects of cemiplimab in patients with aNSCLC (Video 3/3)

    Eric Singhi , MD
    Dr. Charu Aggarwal presents intracranial activity for datopotamab deruxtecan in pretreated mNSCLC (Video 3/3)

    Dr. Charu Aggarwal presents intracranial activity for datopotamab deruxtecan in pretreated mNSCLC (Video 3/3)

    Charu Aggarwal, MD
    Dr. Charu Aggarwal reviews safety highlights for datopotamab deruxtecan in pretreated mNSCLC (Video 2/3)

    Dr. Charu Aggarwal reviews safety highlights for datopotamab deruxtecan in pretreated mNSCLC (Video 2/3)

    Charu Aggarwal, MD
    Dr. Eric Singhi shows that PD-L1 expression is a spectrum in patients with aNSCLC (Video 2/3)

    Dr. Eric Singhi shows that PD-L1 expression is a spectrum in patients with aNSCLC (Video 2/3)

    Eric Singhi , MD
    Dr. Gregory Vidal discusses the safety, tolerability, and patient management techniques for  inavolisib + palbociclib + fulvestrant in 1L PIK3CAm HR+, HER2- ABC (Video 2/2)

    Dr. Gregory Vidal discusses the safety, tolerability, and patient management techniques for inavolisib + palbociclib + fulvestrant in 1L PIK3CAm HR+, HER2- ABC (Video 2/2)

    Gregory Vidal
    ideology-health
    Privacy Policy
    Terms of Service
    Inc. 5000

    IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America

    © 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.